Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 9/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.44 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832764 | 0.93 | CACNA1B (0.49) | GPR132CACNA1BDPP7YAP1MME | |
| SCHEMBL5833266 | 0.88 | TACR2 (0.47) | GPR132YAP1PLGACACBMMP9 | |
| SCHEMBL5833273 | 0.87 | GPR132 (0.44) | GPR132CACNA1BYAP1PLGACACB | |
| SCHEMBL5833964 | 0.86 | GPR132 (0.51) | GPR132CACNA1BDPP7YAP1PLG | |
| SCHEMBL5833515 | 0.85 | CACNA1B (0.46) | CACNA1BDPP7YAP1MMEACE | |
| SCHEMBL5833543 | 0.84 | GPR132 (0.50) | GPR132YAP1PLGACACBCMKLR2 | |
| SCHEMBL5833547 | 0.84 | GPR132 (0.50) | GPR132YAP1PLGACACBCMKLR2 | |
| SCHEMBL5833622 | 0.81 | CTSS (0.49) | YAP1PLGMMEACECPA1 | |
| SCHEMBL5833528 | 0.80 | ACACB (0.50) | GPR132PLGACACBCMKLR2CMKLR1 | |
| SCHEMBL7339830 | 0.80 | CACNA1B (0.68) | CACNA1BDPP7YAP1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | GPR132 192/4885CACNA1B 4/4885DPP7 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.